LivaNova PLC Non-GAAP EPS of $1.23 beats by $0.17, revenue of $393.1M beats by $11.99M (LIVN:NASDAQ)
LivaNova PLC reported Q3 Non-GAAP EPS of $1.23, exceeding estimates by $0.17, with revenue of $393.1M, up 9.9% Y/Y and beating by $11.99M. The company raised FY2026 revenue growth guidance to 9%-10% and adjusted EPS to $4.40-$4.50, above consensus.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift could trigger short‑term buying pressure and re‑rating by analysts.
Market read
First‑report earnings and guidance update for a mid‑cap med‑tech stock, offering a clear trading catalyst.
What to watch
Potential supply‑chain constraints or regulatory hurdles could temper growth.
Background
LivaNova is a medical‑technology company focused on neuromodulation and cardiac surgery devices.
Ticker impact
LivaNova reported Q3 Non‑GAAP EPS of $1.23 beating estimates and raised FY2026 revenue and EPS guidance.
likely upside as investors price in higher revenue and EPS guidance
Guidance increase is material and fresh, prompting re‑rating of the stock.
Market effects
Medical device sector may see modest uplift from higher guidance.
U.S. healthcare stocks could benefit from the positive earnings surprise.
Limited to investors tracking med‑tech earnings; no broad market effect.
Counterpoint
Guidance raise may already be priced in; risk of miss on full‑year targets.
Key entities
- CompanyLivaNova PLC
Medical‑technology firm reporting Q3 results.
